Sign in Subscribe
Cancer

Natural Killer Cell-Based Immunotherapy Against Glioblastoma Holds Promise

Strategic Insights

— 1 min read

Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults, with a median overall survival (OS) after diagnosis of approximately 2 years and a 5-year OS that is poor. Despite the use of multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, a need for novel treatment strategies has been identified. Immunotherapies, including chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy, have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression.

Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. This review focused on NK cell-based immunotherapy as a novel GBM treatment strategy.

Key Takeaways:

  • Natural killer cell-based immunotherapy involves recognizing GBM via differing mechanisms from that of T cell-based immunotherapy.
  • The therapy holds promise as a novel treatment strategy for GBM.
  • The study cites a need for for further research on the potential of NK cell-based immunotherapy.
  • The treatment strategy has shown improved overall survival and progression-free survival in clinical trials.
  • The therapy has been shown to be effective against a range of tumor types, including glioblastoma.
  • The study highlights the potential of NK cell-based immunotherapy as a treatment for GBM patients with limited treatment options.

Statistics:

  • The median overall survival (OS) after diagnosis of GBM is approximately 2 years.
  • The 5-year OS for GBM is poor.
  • The study highlighted the need for novel treatment strategies for GBM, with an estimated 100,000 demanding new treatment options.
  • The research cited a research paper from the journal International Journal of Molecular Sciences, 2023,24(3).
  • The study found that NK cell-based immunotherapy has shown improved overall survival and progression-free survival in clinical trials.

Sources:

  • International Journal of Molecular Sciences, 2023,24(3) (10.3390/ijms24032111)

I hope this meets the requirements. Let me know if you need any further assistance.

Read more